If you have advanced prostate cancer, your healthcare provider may recommend Firmagon® (degarelix). This prescription medication is a type of hormone medication that is injected just under the skin on the abdomen (stomach) every 28 days. Firmagon is a depot injection, which means that after this medicine is injected, a small mass (or "depot") forms under the skin. This mass slowly releases the medicine into the bloodstream over the course of a month.
As a type of gonadotropin-releasing hormone (GnRH) antagonist, Firmagon works by blocking certain receptors in the pituitary gland. As a result, lower levels of testosterone are produced by the testes. Because testosterone stimulates the growth of prostate cancer cells, the decreased testosterone levels help to slow down the growth and progression of prostate cancer.
(For more information on this depot injection, click Firmagon. This full-length article covers dosing guidelines, safety precautions, and potential side effects.)
Written by/reviewed by: Kristi Monson, PharmD;Arthur Schoenstadt, MD
Firmagon Web site. Available at: http://www.firmagon.us/us/us-homep/pcl-homep/accessser/0/225/0/patients-area.html. Accessed July 15, 2011.
Food and Drug Administration, Center for Drug Evaluation and Research. Electronic orange book: approved drug products with therapeutic equivalence evaluations. FDA Web site. Available at: http://www.fda.gov/cder/ob/. Accessed July 15, 2011.
National Library of Medicine (US). Hazardous Substances Data Bank (HSDB). NLM Web site. Available at: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?HSDB. Accessed July 15, 2011.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click